Announcement

Myonex’s Journey on Molecule to Market

In a recent episode of Molecule to Market, host Raman Sehgal sat down with two leaders of Myonex —James Lovett, CEO, and Mike Cohen, Executive Chairman. Their conversation unveiled the evolution of Myonex from a small family-owned pharmacy to a global leader in clinical trial supply.

Spanning three generations, Myonex has successfully navigated industry shifts, scaled through organic growth and acquisitions, and remained steadfast in its commitment to patient-centric and customer-first services and solutions. James and Mike share their insights on the challenges of leadership transitions, the strategic decision to remain family-owned, and the constant evolution of the clinical trial landscape.

Here are some of the takeaways from the conversation, along with the wisdom they shared on building a business that constantly evolves to meet growing demands from the market.

On the Origins of Myonex: A Family-Owned LegacyMike Cohen: “This is a family-owned business. I’m the third generation in the company. My grandfather started it over 90 years ago as a small independent pharmacy in Philadelphia, and that later played into our story as we found opportunities to supply pharma companies in the region.”

On Growing the Business and Knowing When to Step Back

Mike Cohen: “I loved selling and building relationships with clients, but I reached a point where I realized I wasn’t the right person to take Myonex to the next level. That’s why I made the decision to bring in James as CEO.”

On James Lovett’s Transition from Law to Pharma Leadership

James Lovett: “I started as a lawyer, but I always wanted to be closer to the business. My mother’s battle with stage four colon cancer changed my perspective—it made me realize that what we do in this industry isn’t just about business; it’s about making a difference in patients’ lives.”

On the Evolution of Myonex’s Services

James Lovett: “We started in comparator sourcing but saw opportunities to expand into clinical trial packaging, patient-centric solutions like CTRx, and ancillary supplies. Now, with recent acquisitions, we’re also offering bioservices and compounding pharmacy capabilities.”

Get a deeper dive into the conversation.

Don’t miss out on the full, in-depth discussion with Myonex’s leadership.

Listen to the complete podcast and discover more valuable insights.

View podcast on Molecule to Market